http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H08501062-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S436-822 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-744 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-75 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-75 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-744 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127 |
| filingDate | 1993-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1996-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-H08501062-A |
| titleOfInvention | Non-specific cell immunostimulation method |
| abstract | (57) [Summary]nA non-specific and major anti-proliferative cell (macrophages) augmentation technology to enhance bactericidal activity is a phagocytic and biocompatible to stimulate macrophages to enhance oxidative response and bactericidal activity. Use the fine molecule This method does not require toxic or inflammatory micromolecules such as asbestos or smoke or tobacco particulates. This micromolecule is preferably biodegradable. The irritation occurs immediately. Patients receive the benefits of stimulated macrophages for 1-4 days. Experiments have demonstrated a 100-fold or greater increase in oxidative response. This in vivo phagocytic micromolecule, which produces a 100-fold, rapid, short-term oxidative response and enhanced bactericidal properties, has not previously been described for vertebrates or humans. The enhanced oxidative response and killing capacity are non-immunospecific (meaning not one organism or one vaccine) and have broad applicability to both bacteria and viruses simultaneously. The effect proved to show a non-tissue toxic residual effect and potency for 7 days when used repeatedly at monthly intervals. A compound containing macrophage stimulating factor isolated from bronchoalveolar lavage fluid produced in vivo by phagocytic micromolecules can confer the same non-specific macrophage immunity increase. Treatment with compounds containing phagocytic micromolecules or macrophage-stimulating factors is useful in anticipation of trauma, surgery, epidemics, biological warfare and other contact infections, or to prevent these risks Is. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016006084-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2012097112-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2015157848-A |
| priorityDate | 1992-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 123.